Type: Private; Industry: Pharmaceutical industry; Founded: 1983; Headquarters: Lachen, Switzerland; Number of locations: 31; Products: octanate; octanine-F; wilate; Nuwiq;
octagam; gammanorm; rhesonativ; panzyga; albunorm; octaplas; atenativ; octaplex; octaplasLG; fibryga; Revenue: Euro 2.8 billion (2022); Number of employees: 11,573(2022) Therapeutic Areas Patients in 118 countries are treated with products
in the following therapeutic areas: • Haematology: high-purity coagulation factor concentrates for patients with bleeding disorders Haemophilia A, B and von Willebrand Disease.
Products Octapharma medicines treat a broad range of rare and life-threatening congenital and acquired diseases and conditions: – bleeding disorders (hemophilia A / B and
VWD) – over 300 types of primary and secondary immune deficiencies – numerous auto-immune and neurological disorders – acute conditions – critical care issues (including trauma and burn victims) – cancer patients – major surgeries – protection
of new-borns in case of Rh negative pregnancies Production Octapharma converts source plasma into plasma protein products through fractionation and processing.
As of December 31, 2022, Octapharma employs around 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas:
Hematology, Immunotherapy and Critical Care.
Octapharma AG, founded in 1983, is a family-owned pharmaceutical company, and bills itself as “one of the largest human protein manufacturers in the world, developing and
producing human proteins from human plasma and human cell lines.”
The underlying principle of Octapharma’s R&D is the development of therapies based on human proteins either purified from human plasma or produced by recombinant technologies
applied to human cell lines.
[‘Annual report 2022 https://www.octapharma.com/news/press-release/2022/octapharma-group-delivers-strong-growth-in-sales-and-operating-income-in-2021/
2. ^ About us on https://www.octapharma.com/about-us/who-we-are
3. ^ Octapharma Website http://www.octapharma.com/en/patients/diseases-therapies.html
Photo credit: https://www.flickr.com/photos/maf04/6347846687/’]